| Xeomin (incobotulinumtoxinA) / Merz Pharma |
2021-001634-18: A clinical study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy Badanie kliniczne mające na celu zbadanie skuteczności i bezpieczeństwa stosowania NT 201 w leczeniu spastyczności kończyn dolnych u dzieci i młodzieży z mózgowym porażeniem dziecięcym |
|
|
| Not yet recruiting | 3 | 130 | Europe | NT 201, NT 201, Powder for solution for injection, Xeomin | Merz Pharmaceuticals GmbH, Merz Pharmaceuticals GmbH | Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP) Spastyczność kończyn dolnych u dzieci z mózgowym porażeniem dziecięcym., Pediatric lower limb spasticity caused by cerebral palsy. Spastyczność kończyn dolnych u dzieci z mózgowym porażeniem dziecięcym., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 3 | 148 | Europe | IncobotulinumtoxinA (Xeomin), Placebo | Merz Pharmaceuticals GmbH | Post-stroke Upper Limb Spasticity | 11/06 | 05/08 | | |
| Completed | 3 | 256 | Europe | IncobotulinumtoxinA (Xeomin) (20 Units), Placebo | Merz Pharmaceuticals GmbH | Glabellar Frown Lines | 04/07 | 11/07 | | |
NCT00407030: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia |
|
|
| Completed | 3 | 233 | US | incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo | Merz Pharmaceuticals GmbH | Cervical Dystonia | 01/08 | 06/09 | | |
| Completed | 3 | 216 | Europe | incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kD), free from complexing proteins"), incobotulinumtoxinA, Xeomin, NT 201, Botulinum toxin type A (150 kD), free from complexing proteins | Merz Pharmaceuticals GmbH | Upper Limb Spasticity | 01/08 | 05/08 | | |
| Completed | 3 | 111 | Europe | IncobotulinumtoxinA (Xeomin), Placebo | Merz Pharmaceuticals GmbH | Lateral Periorbital Wrinkles | 02/08 | 05/08 | | |
NCT00406367: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm |
|
|
| Completed | 3 | 109 | US, Canada | incobotulinumtoxinA (Xeomin), Placebo | Merz Pharmaceuticals GmbH | Blepharospasm | 04/08 | 07/09 | | |
| Completed | 3 | 108 | Europe | NT 201 | Merz Pharmaceuticals GmbH | Healthy | 01/09 | 01/09 | | |
NCT00770211: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines |
|
|
| Completed | 3 | 271 | US | IncobotulinumtoxinA (Xeomin) (20 Units), IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (20 Units), Placebo | Merz Pharmaceuticals GmbH | Moderate to Severe Glabellar Frown Lines | 03/09 | 06/09 | | |
NCT00770029: IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2 |
|
|
| Completed | 3 | 276 | US, Canada | IncobotulinumtoxinA (Xeomin) (20 Units), IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (20 Units), Placebo | Merz Pharmaceuticals GmbH | Moderate to Severe Glabellar Frown Lines | 03/09 | 06/09 | | |
NCT00777803 / 2008-002713-40: NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines |
|
|
| Completed | 3 | 381 | Europe | NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®)), "Botulinum toxin type A (150 kiloDalton), free from complexing proteins", OnabotulinumtoxinA (Vistabel®), "BOTOX® Cosmetic", "Botulinum toxin type A (900 kiloDalton)" | Merz Pharmaceuticals GmbH | Glabellar Frown Lines | 04/09 | 05/09 | | |
| Completed | 3 | 801 | Europe, Canada, US | IncobotulinumtoxinA (Xeomin) (20 units), IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins (20 units) | Merz Pharmaceuticals GmbH | Glabellar Lines | 12/09 | 12/09 | | |
NCT00986570: Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face |
|
|
| Completed | 3 | 121 | RoW | Botulinum Toxin A, Xeomin® | Biolab Sanus Farmaceutica | Skin Aging | 06/10 | 11/10 | | |
RBHP 2008, NCT00909883: Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles) |
|
|
| Unknown status | 3 | 45 | Europe | Botulinum Toxin: Xeomin, Placebo | University Hospital, Clermont-Ferrand, Merz Pharmaceuticals | Parkinson's Disease, Foot Dystonia | 09/11 | 09/12 | | |
| Completed | 3 | 20 | Canada | Xeomin, Botulinum Toxin A, Placebo / Xeomin, Sodium Chloride, Saline | Innovaderm Research Inc., Merz Pharmaceuticals GmbH | Notalgia Paresthetica | 02/12 | 02/12 | | |
| Completed | 3 | 317 | US, Europe, RoW | IncobotulinumtoxinA (400 Units), Xeomin, Placebo Comparator | Merz Pharmaceuticals GmbH | Post-stroke Spasticity of the Upper Limb | 03/13 | 02/14 | | |
| Completed | 3 | 290 | US, Canada, Europe, RoW | IncobotulinumtoxinA (400 Units), Placebo Comparator | Merz Pharmaceuticals GmbH | Post-stroke Spasticity of the Lower Limb | 08/14 | 05/15 | | |
2013-005088-13: Blocs partiels du droit antérieur et du soléaire avec la toxine botulique de type A (Xeomin®) pour l'amélioration de la marche chez l'hémiparétique. Essai randomisé multicentrique contrôlé contre placebo. |
|
|
| Not yet recruiting | 3 | 66 | Europe | XEOMIN, Powder for injection, XEOMIN | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | Hémiparésie par accident vasculaire cérébral (AVC) ou traumatise crânien (TC) depuis plus de 6 mois. | | | | |
| Completed | 3 | 155 | US, Canada, Europe | IncobotulinumtoxinA | Merz Pharmaceuticals GmbH | Spasticity of the Upper and Lower Limb Due to Cerebral Causes | 09/14 | 09/14 | | |
NCT01893411 / 2012-005054-30: Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy |
|
|
| Completed | 3 | 311 | Europe, RoW | IncobotulinumtoxinA (16 Units per kg body weight), Xeomin, NT 201, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, IncobotulinumtoxinA (12 Units per kg body weight), IncobotulinumtoxinA (4 Units per kg body weight) | Merz Pharmaceuticals GmbH | Lower Limb Spasticity Due to Cerebral Palsy | 08/15 | 05/16 | | |
SIAXI, NCT02091739 / 2012-005539-10: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions |
|
|
| Completed | 3 | 184 | Europe | IncobotulinumtoxinA (100 Units), Xeomin, NT 201, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, IncobotulinumtoxinA (75 Units), Placebo | Merz Pharmaceuticals GmbH | Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury | 08/15 | 11/16 | | |
2006-003036-30: Prospective, randomized, observer-blind, parallel-group, multi-center trial to assess efficacy and safety of two different dilutions of NT 201 in patients with upper limb spasticity |
|
|
| | 3 | 72 | Europe | Xeomin, NT 201, Xeomin, Xeomin | Merz Pharmaceuticals GmbH, MERZ PHARMACEUTICALS GMBH | Chronic upper limb spasticity caused by diverse etiologies | | 07/08 | | |
2011-005887-20: Study with two injections (one injection with placebo or drug, one injectionwith drug) to investigate the efficacy and safety of NT 201 (activeingredient: Botulinum (neuro)toxin type A, free from complexing proteins)in the combined treatment of wrinkles in the upper face. |
|
|
| | 3 | 90 | Europe | NT 201, NT 201, Xeomin, Xeomin | Merz Pharmaceuticals GmbH, Merz Pharmaceuticals GmbH, Merz Pharmaceuticals GmbH, Germany | Upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral periorbital lines) | | 10/13 | | |
2015-003184-11: Functional effects of botulinum toxin in the hip adductors and subsequent exercise in HSP patients Functionele effecten van botulinetoxine in de heup adductoren en daaropvolgende oefeningen bij HSP patiënten. |
|
|
| Ongoing | 3 | 30 | Europe | Solution for injection, Xeomin | Radboud University Medical Centre, Radboud University Medical Centre | Hereditary Spastic Paraplegia Hereditaire Spastische Paraplegie, HSP HSP, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT01896895 / 2012-004821-26: Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid |
|
|
| Completed | 3 | 61 | Europe, RoW | IncobulinumtoxinA (Xeomin), 25 Units, NT 201, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, IncobotulinumtoxinA (Xeomin), 12.5 Units, Placebo, IncobotulinumtoxinA (Xeomin), 35 Units | Merz Pharmaceuticals GmbH | Bilateral Blepharospasm (BEB) | 04/16 | 11/16 | | |
2014-003770-16: Open label study with up to four repeated injections to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face. |
|
|
| Completed | 3 | 130 | Europe | NT 201, NT 201, Powder for solution for injection, Xeomin | Merz Pharmaceuticals GmbH, Merz Pharmaceuticals GmbH | Upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral periorbital lines), Moderate to severe wrinkles in the upper face, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT01905683 / 2012-005055-17: Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy |
|
|
| Completed | 3 | 370 | Europe, RoW | IncobotulinumtoxinA (16-20 Units per kg body weight), Xeomin, NT 201, Botulinum toxin type A (150 kiloDalton), free from complexing proteins | Merz Pharmaceuticals GmbH | Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy | 01/17 | 01/17 | | |
2017-001216-11: botulinum toxin for the treatment of chronic anal fissure Toxina botulínica para el tratamiento de la fisura anal crónica |
|
|
| Ongoing | 3 | 100 | Europe | IncobotulinumtoxinA, IncobotulinumtoxinA, Powder for solution for injection, Xeomin® | Dra. A. Teresa Calderón Duque, NA | Chronic anal fissure Fisura anal crónica, Chronic anal fissure Fisura anal crónica, Not possible to specify | | | | |
XARA, NCT02002884 / 2012-005496-14: Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy |
|
|
| Completed | 3 | 351 | Europe, US, RoW | IncobotulinumtoxinA (8 Units per kg body weight), Xeomin, NT 201, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight) | Merz Pharmaceuticals GmbH | Cerebral Palsy, Spasticity | 07/17 | 08/18 | | |
2016-000740-34: Treatment of continuous tearing with Botulinum Toxin versus the inferior eyelid tightening technique Tratamiento del lagrimeo continuo con Toxina Botulínica frente a la técnica de tensado del párpado inferior |
|
|
| Ongoing | 3 | 24 | Europe | IncobotulinumtoxinA, IncobotulinumtoxinA, Powder and solution for solution for injection, Xeomin® | Dr. Borja Maroto Rodríguez, NA | Functional Epifora Epífora funcional, Continuous tearing Lagrimeo continuo, Diseases [C] - Eye Diseases [C11] | | | | |
| Not yet recruiting | 3 | 150 | Europe | Xeomin, Hydrocortancyl, Powder for injection, Suspension for injection, Xeomin, Hydrocortancyl | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Patients suffering from unilateral lateral epicondylitis, persistent for more than 3 months or recurrent and not having responded to at least one reference treatment Patients ayant une épicondylite latérale unilatérale, persistante depuis plus de 3 mois ou récidivante et n'ayant pas répondu à au moins un traitement de référence, NA NA, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
SIPEXI, NCT02270736 / 2013-004532-30: Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability |
|
|
| Completed | 3 | 256 | Europe, RoW | NT 201 Placebo, NT 201, IncobotulinumtoxinA, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins | Merz Pharmaceuticals GmbH | Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke, Traumatic Brain Injury, Intellectual Disability | 02/18 | 05/19 | | |
2016-003949-28: Efficacy and tolerability of incobotulinumtoxin A in comparison with onabotulinumtoxinA in patients with overactive bladder syndrome. Efficacia e tollerabilit¿ della incobotulinumtoxin A in confronto alla onabotulinumtoxin A nella terapia di pazienti con vescica iperattiva. |
|
|
| Not yet recruiting | 3 | 140 | Europe | xeomin, botox, Powder for solution for injection, XEOMIN - 100 UNITA' DL50 POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO DI VETRO, BOTOX - 100 UNIT¿ ALLERGAN POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO | PROF. ANTONELLA GIANNANTONI - CLINICA UROLOGICA - UNIVERSITà DI PERUGIA, Clinica Urologica ad indirizzo Oncologico | neurogenic overactive bladder Vescica iperattiva neurogena, neurogenic overactive bladder Vescica iperattiva neurogena, Diseases [C] - Symptoms and general pathology [C23] | | | | |
2018-002929-36: EFFICACY OF CORTICOIDS VS BOTULINIC TOXIN IN THE TREATMENT OF PLANTAR FASCITIS EFICACIA DE CORTICOIDES VS TOXINA BOTULÍNICA EN EL TRATAMIENTO DE LA FASCITIS PLANTAR |
|
|
| Not yet recruiting | 3 | 70 | Europe | IncobotulinumtoxinA, Triamcinolona acetónido, IncobotulinumtoxinA, Triamcinolona acetónido, Powder for solution for injection, Suspension for injection, Xeomin®, TRIGON DEPOT® | Dra. Virginia Raquel Céspedes Nava, NA | Plantar fasciitis Fascitis plantar, Plantar fasciitis Fascitis plantar, Body processes [G] - Physical Phenomena [G01] | | | | |
2018-002541-11: Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in patients undergoing cardiac surgery Prévention de la Fibrillation Atriale postopératoire par l’injection de Toxine BOtulique autour des veines pulmonaires chez les patients ayant une chirurgie cardiaque |
|
|
| Not yet recruiting | 3 | 220 | Europe | XEOMIN, Powder for solution for injection, Xeomin® 200 U | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), Ministry of Health | Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery) will be eligible Seront éligibles : les patients adultes (>/= 18 ans) avec indication à une chirurgie cardiaque selon les recommandations de la Société Européenne de Cardiologie (ESC) : pontages coronaires, remplacements valvulaires aortiques, remplacements de l’aorte ascendante, Adult patients with indication for conventional cardiac surgery Patients adultes avec indication à une chirurgie cardiaque selon les recommandations de la Société Européenne de Cardiologie, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ULTRA I, NCT04594213: Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines |
|
|
| Completed | 3 | 362 | US | NT 201, IncobotulinumtoxinA, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing protein, Placebo | Merz North America, Inc., Merz Pharmaceuticals GmbH | Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines) | 04/21 | 05/22 | | |
ULTRA II, NCT04622254: Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines. |
|
|
| Completed | 3 | 368 | Europe | NT 201, IncobotulinumtoxinA, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing protein, Placebo | Merz Pharmaceuticals GmbH | Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines) | 06/21 | 07/22 | | |
NCT03758235: Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin |
|
|
| Active, not recruiting | 3 | 140 | Europe | IncobotulinumtoxinA 100 UNT Injection [Xeomin], Incobot/A, OnabotulinumtoxinA 100 UNT [Botox], Onabot/A | University Of Perugia | Overactive Bladder Syndrome | 09/21 | 09/21 | | |
2022-000842-14: Effectiveness of botulinum toxin A injection in reducing the pain and size of painful scars Efectividad de la inyección de toxina botulínica A para reducir el dolor y tamaño de las cicatrices dolorosas |
|
|
| Not yet recruiting | 3 | 20 | Europe | IncobotulinumtoxinA, IncobotulinumtoxinA, Powder for solution for injection, Xeomin® | Dra.Margarita Ramirez&Dra.Ifara Sánchez, NA | painful scars Cicatrices dolorosas, painful scars Cicatrices dolorosas, Not possible to specify | | | | |
2019-004113-13: Safety and efficacy study of the simultaneous treatment of upper facial lines (horizontal forehead lines, glabellar frown lines and crows feet) in subjects with moderate to severe upper facial lines. |
|
|
| Not yet recruiting | 3 | 360 | Europe | Bocouture, NT 201, Powder for solution for injection, Bocouture (100 Units) | Merz Pharmaceuticals GmbH, Merz Pharmaceutical GmbH | Moderate to severe upper facial lines(horizontal forehead lines, glabellar frown lines, and lateral canthal lines), Moderate to severe upper facial lines(horizontal forehead lines, glabellar frown lines, and crows feed Falten des oberen Gesichtsbereiches(horizontale Stirnfalten, Zornesfalten und Krähenfüße), Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Recruiting | 3 | 220 | Europe | Botulinum Toxin Type A Injection [Xeomin], Xeomin, Drug placebo | Assistance Publique - Hôpitaux de Paris, Merz Pharmaceuticals, Ministry of Health, France | Cardiac Surgery | 10/24 | 09/25 | | |
2020-006147-25: Botulinum toxin type A injection in patients with chronic pelvic pain of uterine origin Phase III, single-center, randomized study vs. control group Injection de Toxine botulinique de type A chez des patientes atteintes de douleurs pelviennes chroniques d’origine utérine Étude de phase III, monocentrique, randomisée vs groupe contrôle |
|
|
| Ongoing | 3 | 100 | Europe | Toxine botulinique, Powder for solution for injection, XEOMIN 200 | Centre de Recherche en Santé de la Femme, Centre de Recherche en Santé de la Femme, Laboratoire MERZ | PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4 PATIENTES PRÉSENTANT DES DOULEURS PELVI-PERINEALES CHRONIQUES D'ORIGINE UTÉRINE AVEC EVA>4, PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4 PATIENTES PRÉSENTANT DES DOULEURS PELVI-PERINEALES CHRONIQUES D'ORIGINE UTÉRINE AVEC EVA>4, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
NCT05623410: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines |
|
|
| Active, not recruiting | 3 | 300 | RoW | ATGC-110, Clostridium Botulinum Type A, Xeomin®, Incobotulinumtoxin A | ATGC Co., Ltd. | Glabellar Frown Lines | 02/23 | 06/23 | | |
2022-004127-40: effectiveness and safety of botulinum toxin type A in doses adapted for patients with severe spasticity efectividad y seguridad de la toxina botulínica tipo A en dosis adaptadas para pacientes con cuadros de espasticidad severa |
|
|
| Not yet recruiting | 3 | 30 | Europe | IncobotulinumtoxinA, IncobotulinumtoxinA, Powder for solution for injection, Xeomin | Dra. Nuria Gutierrez Dubón, NA | brain damage oriented spasticity Espasticidad orientada al daño cerebral, spasticity Espasticidad, Not possible to specify | | | | |
NCT05980559: Evaluation of BTX Injections in Treatment of Bruxism |
|
|
| Not yet recruiting | 3 | 12 | NA | Xeomin | Alexandria University | Bruxism | 01/24 | 04/24 | | |
NCT03977493: IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia |
|
|
| Recruiting | 3 | 48 | Europe | Xeomin, Placebo - Concentrate | Alain Kaelin, Clinical Trial Unit Ente Ospedaliero Cantonale | Focal Hand Dystonia | 12/24 | 12/24 | | |
NCT06205797: To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III) |
|
|
| Not yet recruiting | 3 | 312 | NA | HU-045, Xeomin® | Huons Biopharma | Glabellar Lines | 09/24 | 07/25 | | |
| Recruiting | 3 | 128 | US | IncobotulinumtoxinA (XEOMIN®), Xeomin, OnabotulinumtoxinA (BOTOX®), Botox | Naval Medical Center Camp Lejeune | Chronic Migraine | 02/25 | 08/25 | | |
PATTERN, NCT03992404 / 2018-001639-35: Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury |
|
|
| Recruiting | 3 | 600 | Europe, US, RoW | NT 201, IncobotulinumtoxinA, Incobotulinumtoxin A, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, Placebo | Merz Pharmaceuticals GmbH | Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury | 08/25 | 04/27 | | |
